Celgene/Agios Team Up In Long-Term Cancer Metabolism Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
Agios will receive $130 million upfront, while Celgene gains the option to develop any drugs resulting from the biotech's cancer metabolism research platform for an undisclosed period of time.